title: Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.
abstract: BACKGROUND
  There is no standard second-line treatment for advanced urothelial carcinoma (UC). Response rates to second-line chemotherapy for advanced UC are low and response duration is short. Bortezomib is a proteasome inhibitor with preclinical activity against UC.
  
  
  METHODS
  Treatment consisted of bortezomib 1.3 mg/m(2) i.v. twice weekly for two consecutive weeks, followed by a 1-week break. The primary end point was objective response rate (complete response + partial response) by Response Evaluation Criteria in Solid Tumors criteria. Secondary end points included safety, toxicity, and progression-free and overall survival.
  
  
  RESULTS
  In all, 25 patients with advanced UC previously treated with combination chemotherapy were enrolled in a multi-institutional single-arm trial from December 2003 through April 2005. Only 29% of patients had node-only metastases. Grade 3/4 drug-related toxic effects included thrombocytopenia (4%), anemia (8%), lymphopenia (8%), sensory neuropathy (6%), hyperglycemia (4%), hypernatremia (4%), fatigue (4%), neuropathic pain (6%), dehydration (4%), and vomiting (4%). No objective responses were observed [95% confidence interval (CI) = 0-12]. The median time to progression was 1.4 months (95% CI = 1.1-2.0 months), and the median survival time was 5.7 months (95% CI = 3.6-8.4 months). There were no treatment-related deaths.
  
  
  CONCLUSIONS
  Although bortezomib is well tolerated, it does not have antitumor activity as second-line therapy in UC.
authors.affiliation: Division of Hematology and Oncology, University of California, San Francisco Cancer Center, San Francisco, CA 94115, USA. jrosenbe@medicine.ucsf.edu
authors.forename: J E
authors.initials: JE
authors.lastname: Rosenberg
authors.forename: S
authors.initials: S
authors.lastname: Halabi
authors.forename: B L
authors.initials: BL
authors.lastname: Sanford
authors.forename: A L
authors.initials: AL
authors.lastname: Himelstein
authors.forename: J N
authors.initials: JN
authors.lastname: Atkins
authors.forename: R J
authors.initials: RJ
authors.lastname: Hohl
authors.forename: F
authors.initials: F
authors.lastname: Millard
authors.forename: D F
authors.initials: DF
authors.lastname: Bajorin
authors.forename: E J
authors.initials: EJ
authors.lastname: Small
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D016879:Salvage Therapy; D017211:Treatment Failure; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib